Inhibitor Therapeutics, Inc. (INTI)

0.1206 -0.0094 (-7.22%) 收市：11:24AM EDT

Inhibitor Therapeutics, Inc.

4905 South West Shore Blvd
Tampa, FL 33611-3329
United States
813 864 2562
https://inhibitortx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 3

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Francis E. O'Donnell Jr., M.D.	Founder, Executive Chairman & CEO	1.09M	無	1950
Mr. James A. McNulty CPA	Interim CFO, Treasurer & Secretary	337.96k	無	1950

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc is a subsidiary of Mayne Pharma Ventures Pty Ltd.

公司管治

截至 無 止，Inhibitor Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。